FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204334789> ?p ?o ?g. }

• W3204334789 endingPage "e754" @default.
• W3204334789 startingPage "e753" @default.
• W3204334789 abstract "Persistence of antibody response after two-dose SARS-CoV-2 mRNA vaccination has been shown for up to 6 months in immunocompetent populations.1Doria-Rose N Suthar MS Makowski M et al.Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19.N Engl J Med. 2021; 384: 2259-2261Crossref PubMed Scopus (445) Google Scholar We previously confirmed a robust SARS-CoV-2 antibody response in most patients with rheumatic and musculoskeletal diseases; however, we found attenuated responses in patients on lymphocyte depleting agents.2Ruddy JA Connolly CM Boyarsky BJ et al.High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.Ann Rheum Dis. 2021; 80: 1351-1352Crossref PubMed Scopus (90) Google Scholar Although antibody titres among organ transplant recipients 3 months after completion of an mRNA vaccine series were mostly stable,3Boyarsky BJ Chiang TPY Teles AT et al.Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients.Transplantation. 2021; (published online June 25.)https://doi.org/10.1097/TP.0000000000003863Crossref Scopus (15) Google Scholar the kinetics of antibody response in other immunosuppressed populations remain to be defined. Here, we present anti-spike antibody titres over a 3-month period in patients with rheumatic and musculoskeletal disease who completed the two-dose SARS-CoV-2 mRNA vaccine series. We included patients with rheumatic and musculoskeletal disease on immunosuppressive medication who received two doses of mRNA (BNT162b2 [tozinameran] Pfizer–BioNTech or mRNA-1273 [elasomeran] Moderna) SARS-CoV-2 vaccine. Participants were recruited via social media postings by national rheumatic and musculoskeletal diseases organisations and advocacy groups, as well as through clinician referral. Baseline demographics and clinical characteristics were collected via electronic questionnaire. Participants with previous SARS-CoV-2 infection were excluded. Antibody testing was done 1 month and 3 months after dose 2 with the Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay (EIA); range <0·4 to >250·0 U/mL [positive test result was ≥0·8 U/mL]), which tests for antibodies against the receptor binding domain (RBD) of the spike protein. Participants completed vaccination between Jan 4 and April 21, 2021. Low-positive antibody response was defined as anti-RBD pan Ig of 0·8–50 units per mL; high-positive antibody response was defined as anti-RBD pan immunoglobulin of more than 50 units per mL.3Boyarsky BJ Chiang TPY Teles AT et al.Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients.Transplantation. 2021; (published online June 25.)https://doi.org/10.1097/TP.0000000000003863Crossref Scopus (15) Google Scholar This study was approved by the Johns Hopkins Institutional Review Board (IRB00248540), and patients provided electronic informed consent. We assessed serial samples from 809 participants. 745 (92%) were female, with a median age of 49 years (IQR 39–59). Inflammatory arthritis (355 [44%] participants), overlap connective tissue disease (188 [23%]), and systemic lupus erythematosus (147 [18%]) were the most common rheumatic and musculoskeletal disease diagnoses. Hydroxychloroquine (322 [40%]) and methotrexate (209 [26%]) were the most frequently reported conventional disease modifying anti-rheumatic drugs, whereas tumour necrosis factor alpha (TNFα) inhibitor therapy was the most common biologic agent (173 [21%]; appendix pp 1–2). 744 (92%) of 809 participants had a positive anti-spike antibody response at a median of 29 days (IQR 28–32) after dose 2 and 753 (93%) had detectable anti-spike antibody responses at a median of 91 days (87–94) after dose 2. Titres remained stable in 724 (89%) participants between 1 month and 3 months after completion of the vaccination series (table). Titres decreased in 37 (5%) of 809 participants, whereas an increase in titres was observed in 88 (11%) participants.TableAnti-spike antibody responses 3 months after two doses of SARS-CoV-2 vaccine stratified by antibody responses 1 month after two-dose mRNA vaccine series in patients (n=809) with rheumatic and musculoskeletal diseasesNegative antibody response at 3 months (n=56)Low-positive antibody responses at 3 months (n=77)High-positive antibody responses at 3 months (n=676)Negative antibody response at 1 month (n=65)50 (77%)9 (14%)6 (9%)Low-positive antibody response at 1 month (n=75)5 (7%)37 (49%)33 (44%)High-positive antibody response at 1 month (n=669)1 (<1%)31 (5%)637 (95%)Data are n (%), where the denominator is the number of patients with responses at 1 month. Open table in a new tab Data are n (%), where the denominator is the number of patients with responses at 1 month. Among 669 participants with high-positive titres at 1 month, 637 (95%) remained stable and 32 (5%) had a reduction in titres by 3 months. Among 75 participants with low-positive titres at 1 month, 37 (49%) remained stable, 33 (44%) had high-positive responses, and five (7%) had titres that dropped below the threshold of positivity. Among 65 participants with negative antibody response at 1 month, 50 (77%) remained negative, while de novo antibody responses were seen in 15 (23%) participants at 3 months (table). All 15 participants with de novo response reported use of antimetabolite therapy, including azathioprine or mycophenolate. This finding might suggest delayed response in patients on lymphodepleting therapy (appendix p 3). Supporting this observation, among patients with low-positive titres at 1 month and high-positive titres at 3 months, 27 (82%) of 33 were on antimetabolite therapy. 56 (7%) of 809 participants did not have detectable antibody response at 3 months; the most common immunosuppressive agents in this group included rituximab (33 [59%] of 56), glucocorticoids (26 [46%]), mycophenolate mofetil or mycophenolic acid (16 [29%]), and methotrexate (14 [25%]), which have previously been associated with blunted responses to SARS-CoV-2 vaccination.2Ruddy JA Connolly CM Boyarsky BJ et al.High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.Ann Rheum Dis. 2021; 80: 1351-1352Crossref PubMed Scopus (90) Google Scholar Our study is limited by the absence of an immunocompetent control group, data on memory B-cell and cellular responses, and medication doses for all participants. The Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay is limited by a low ceiling titre of 250 U/mL, precluding detection of decreasing antibody titres in those with titres above this threshold. We included patients without previous known SARS-CoV-2 infection, but because we did not complete anti-nucleocapsid testing, asymptomatic infection at any point in the study cannot be excluded. In conclusion, we found that rates of seropositivity remained largely stable in most of our population with rheumatic and musculoskeletal disease at 3 months after completion of a two-dose mRNA SARS-CoV-2 vaccination series. We observed increased antibody titres in 6% of participants, which might suggest delayed immune response in those on specific immunosuppressive therapies. Although correlates of protection against SARS-CoV-2 infection are not yet established, one study estimated that an antibody neutralisation level for 50% protection against detectable SARS-CoV-2 infection to be 20% of the mean concentration reported in assays of convalescent serum samples.4Khoury DS Cromer D Reynaldi A et al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.Nat Med. 2021; 27: 1205-1211Crossref PubMed Scopus (2068) Google Scholar Breakthrough SARS-CoV-2 infections in fully vaccinated patients with rheumatic and musculoskeletal disease resulting in severe disease and death have been reported, and immunosuppressed status has been associated with an increased risk of infection despite vaccination.5Brosh-Nissimov T Orenbuch-Harroch E Chowers M et al.BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.Clin Microbiol Infect. 2021; (published online July 7.)https://doi.org/10.1016/j.cmi.2021.06.036Summary Full Text Full Text PDF PubMed Scopus (197) Google Scholar These findings have prompted the US Center for Disease Control and Protection to recommend third dose vaccination for patients with moderate-to-severe disease on immunosuppressive drugs. Longitudinal studies to further understand kinetics of antibody titres over time and to determine thresholds for protection could inform the optimal vaccination schedule for patients with rheumatic and musculoskeletal disease on immunosuppressive medication to ensure durable protective immunity. All authors contributed to the creation of this manuscript in all aspects including data gathering, analysis, writing, and critical revision. DLS reports consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. LC-S reports consultant fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, EMD-Serono, Allogene, Roivant, Octapharma, and ArgenX. All other authors report no competing interests. This research was made possible with the generous support of the Ben-Dov family. This work was supported by grant number 5T32DK007713 (JLA) and F32DK124941 (BJB) from the National Institute of Diabetes and Digestive and Kidney Diseases; K24AI144954 (DLS) from the National Institute of Allergy and Infectious Diseases; and K23AR073927 (JJP) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government. Download .pdf (.19 MB) Help with pdf files Supplementary appendix" @default.
• W3204334789 created "2021-10-11" @default.
• W3204334789 creator A5009105677 @default.
• W3204334789 creator A5025008545 @default.
• W3204334789 creator A5030533822 @default.
• W3204334789 creator A5043750897 @default.
• W3204334789 creator A5059660192 @default.
• W3204334789 creator A5060077570 @default.
• W3204334789 creator A5070979049 @default.
• W3204334789 creator A5076022988 @default.
• W3204334789 creator A5081164244 @default.
• W3204334789 creator A5088963892 @default.
• W3204334789 date "2021-11-01" @default.
• W3204334789 modified "2023-10-17" @default.
• W3204334789 title "Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination" @default.
• W3204334789 cites W3142193311 @default.
• W3204334789 cites W3163785571 @default.
• W3204334789 cites W3164014942 @default.
• W3204334789 cites W3179335016 @default.
• W3204334789 doi "https://doi.org/10.1016/s2665-9913(21)00282-4" @default.
• W3204334789 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8550901" @default.
• W3204334789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34725649" @default.
• W3204334789 hasPublicationYear "2021" @default.
• W3204334789 type Work @default.
• W3204334789 sameAs 3204334789 @default.
• W3204334789 citedByCount "11" @default.
• W3204334789 countsByYear W32043347892021 @default.
• W3204334789 countsByYear W32043347892022 @default.
• W3204334789 countsByYear W32043347892023 @default.
• W3204334789 crossrefType "journal-article" @default.
• W3204334789 hasAuthorship W3204334789A5009105677 @default.
• W3204334789 hasAuthorship W3204334789A5025008545 @default.
• W3204334789 hasAuthorship W3204334789A5030533822 @default.
• W3204334789 hasAuthorship W3204334789A5043750897 @default.
• W3204334789 hasAuthorship W3204334789A5059660192 @default.
• W3204334789 hasAuthorship W3204334789A5060077570 @default.
• W3204334789 hasAuthorship W3204334789A5070979049 @default.
• W3204334789 hasAuthorship W3204334789A5076022988 @default.
• W3204334789 hasAuthorship W3204334789A5081164244 @default.
• W3204334789 hasAuthorship W3204334789A5088963892 @default.
• W3204334789 hasBestOaLocation W32043347891 @default.
• W3204334789 hasConcept C104317684 @default.
• W3204334789 hasConcept C105580179 @default.
• W3204334789 hasConcept C116675565 @default.
• W3204334789 hasConcept C121332964 @default.
• W3204334789 hasConcept C126322002 @default.
• W3204334789 hasConcept C148898269 @default.
• W3204334789 hasConcept C159047783 @default.
• W3204334789 hasConcept C159654299 @default.
• W3204334789 hasConcept C203014093 @default.
• W3204334789 hasConcept C22070199 @default.
• W3204334789 hasConcept C2779134260 @default.
• W3204334789 hasConcept C3006700255 @default.
• W3204334789 hasConcept C3007834351 @default.
• W3204334789 hasConcept C3008058167 @default.
• W3204334789 hasConcept C524204448 @default.
• W3204334789 hasConcept C54355233 @default.
• W3204334789 hasConcept C62520636 @default.
• W3204334789 hasConcept C71924100 @default.
• W3204334789 hasConcept C86803240 @default.
• W3204334789 hasConceptScore W3204334789C104317684 @default.
• W3204334789 hasConceptScore W3204334789C105580179 @default.
• W3204334789 hasConceptScore W3204334789C116675565 @default.
• W3204334789 hasConceptScore W3204334789C121332964 @default.
• W3204334789 hasConceptScore W3204334789C126322002 @default.
• W3204334789 hasConceptScore W3204334789C148898269 @default.
• W3204334789 hasConceptScore W3204334789C159047783 @default.
• W3204334789 hasConceptScore W3204334789C159654299 @default.
• W3204334789 hasConceptScore W3204334789C203014093 @default.
• W3204334789 hasConceptScore W3204334789C22070199 @default.
• W3204334789 hasConceptScore W3204334789C2779134260 @default.
• W3204334789 hasConceptScore W3204334789C3006700255 @default.
• W3204334789 hasConceptScore W3204334789C3007834351 @default.
• W3204334789 hasConceptScore W3204334789C3008058167 @default.
• W3204334789 hasConceptScore W3204334789C524204448 @default.
• W3204334789 hasConceptScore W3204334789C54355233 @default.
• W3204334789 hasConceptScore W3204334789C62520636 @default.
• W3204334789 hasConceptScore W3204334789C71924100 @default.
• W3204334789 hasConceptScore W3204334789C86803240 @default.
• W3204334789 hasFunder F4320337355 @default.
• W3204334789 hasFunder F4320337357 @default.
• W3204334789 hasFunder F4320337362 @default.
• W3204334789 hasIssue "11" @default.
• W3204334789 hasLocation W32043347891 @default.
• W3204334789 hasLocation W32043347892 @default.
• W3204334789 hasLocation W32043347893 @default.
• W3204334789 hasLocation W32043347894 @default.
• W3204334789 hasOpenAccess W3204334789 @default.
• W3204334789 hasPrimaryLocation W32043347891 @default.
• W3204334789 hasRelatedWork W3009669391 @default.
• W3204334789 hasRelatedWork W3036305013 @default.
• W3204334789 hasRelatedWork W3036314732 @default.
• W3204334789 hasRelatedWork W3127693599 @default.
• W3204334789 hasRelatedWork W4200329650 @default.
• W3204334789 hasRelatedWork W4205317059 @default.
• W3204334789 hasRelatedWork W4206669628 @default.
• W3204334789 hasRelatedWork W4210401150 @default.
• W3204334789 hasRelatedWork W4382894326 @default.

• next